These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10850951)

  • 1. A kinetic study on the interaction between tazobactam (a penicillanic acid sulphone derivative) and active-site serine beta-lactamases.
    Perilli M; Franceschini N; Bonfiglio G; Segatore B; Stefani S; Nicoletti G; Perez MM; Bianchi C; Zollo A; Amicosante G
    J Enzyme Inhib; 2000; 15(1):1-10. PubMed ID: 10850951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Kinetic Study on the Interaction between Tazobactam (A Penicillanic Acid Sulphone Derivative) and Active-Site Serine beta-Lactamases.
    Perilli M; Franceschini N; Bonfiglio G; Segatore B; Stefani S; Nicoletti G; Tavio Perez Md ; Bianchi C; Zollo A; Amicosante G
    J Enzyme Inhib; 1999 Nov; 15(1):1-10. PubMed ID: 10938530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of bacterial strains producing sulbactam- or tazobactam-sensitive beta-lactamases by the use of disks containing the inhibitors alone instead of combining them with antibiotics.
    Banic S
    APMIS; 2006 Jan; 114(1):3-9. PubMed ID: 16499654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationship of 6-methylidene penems bearing tricyclic heterocycles as broad-spectrum beta-lactamase inhibitors: crystallographic structures show unexpected binding of 1,4-thiazepine intermediates.
    Venkatesan AM; Gu Y; Dos Santos O; Abe T; Agarwal A; Yang Y; Petersen PJ; Weiss WJ; Mansour TS; Nukaga M; Hujer AM; Bonomo RA; Knox JR
    J Med Chem; 2004 Dec; 47(26):6556-68. PubMed ID: 15588091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant.
    Sun T; Bethel CR; Bonomo RA; Knox JR
    Biochemistry; 2004 Nov; 43(44):14111-7. PubMed ID: 15518561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spirocyclopropyl beta-lactams as mechanism-based inhibitors of serine beta-lactamases. Synthesis by rhodium-catalyzed cyclopropanation of 6-diazopenicillanate sulfone.
    Sandanayaka VP; Prashad AS; Yang Y; Williamson RT; Lin YI; Mansour TS
    J Med Chem; 2003 Jun; 46(13):2569-71. PubMed ID: 12801220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
    Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
    Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR; Hujer AM; Helfand MS; Bonomo RA
    FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
    Liu Q; Rand K; Derendorf H
    Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of penam sulfones as inhibitors of beta-lactamases.
    Phillips OA; Reddy AV; Setti EL; Spevak P; Czajkowski DP; Atwal H; Salama S; Micetich RG; Maiti SN
    Bioorg Med Chem; 2005 Apr; 13(8):2847-58. PubMed ID: 15781395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
    Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of beta-lactamases by 6,6-bis(hydroxylmethyl)penicillanate.
    Nagase T; Golemi D; Ishiwata A; Mobashery S
    Bioorg Chem; 2001 Jun; 29(3):140-5. PubMed ID: 11437389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 beta-lactamase: 1.63 A crystal structure.
    Padayatti PS; Helfand MS; Totir MA; Carey MP; Hujer AM; Carey PR; Bonomo RA; van den Akker F
    Biochemistry; 2004 Feb; 43(4):843-8. PubMed ID: 14744126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 beta-lactamase: Raman crystallographic evidence.
    Totir MA; Cha J; Ishiwata A; Wang B; Sheri A; Anderson VE; Buynak J; Mobashery S; Carey PR
    Biochemistry; 2008 Apr; 47(13):4094-101. PubMed ID: 18324783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of inhibition of the carbenicillin-hydrolyzing beta-lactamase PSE-4 by the clinically used mechanism-based inhibitors.
    Therrien C; Kotra LP; Sanschagrin F; Mobashery S; Levesque RC
    FEBS Lett; 2000 Mar; 470(3):285-92. PubMed ID: 10745083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of tazobactam with Staphylococcus aureus PC1 beta-lactamase: a molecular modelling and enzyme kinetics study.
    Denny BJ; Toomer CA; Lambert PA
    Microbios; 1994; 78(317):245-57. PubMed ID: 8078414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.
    Helfand MS; Totir MA; Carey MP; Hujer AM; Bonomo RA; Carey PR
    Biochemistry; 2003 Nov; 42(46):13386-92. PubMed ID: 14621983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design of beta-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams.
    Heinze-Krauss I; Angehrn P; Charnas RL; Gubernator K; Gutknecht EM; Hubschwerlen C; Kania M; Oefner C; Page MG; Sogabe S; Specklin JL; Winkler F
    J Med Chem; 1998 Oct; 41(21):3961-71. PubMed ID: 9767633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.